Get the Stockscreener App
0.345
0.88%
0.003
After Hours:
.31
-0.035
-10.14%
Theriva Biologics Inc stock is traded at $0.345, with a volume of 545.69M.
It is up +0.88% in the last 24 hours and down -10.76% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.342
Open:
$0.4349
24h Volume:
545.69M
Relative Volume:
42.12
Market Cap:
$3.31M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-0.2974
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
-18.07%
1M Performance:
-10.76%
6M Performance:
-75.59%
1Y Performance:
-77.00%
1-Day Range:
$0.3416
$0.85
1-Week Range:
$0.283
$0.85
52-Week Range:
$0.283
$2.64
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.345 | 6.05M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Theriva Biologics Inc Stock (TOVX) Latest News
Why Theriva Biologics Inc. stock could rally in 2025Watch List & Verified Momentum Stock Alerts - newser.com
Custom watchlist performance reports with Theriva Biologics Inc.Weekly Stock Summary & Free Expert Verified Stock Movement Alerts - newser.com
How Theriva Biologics Inc. stock reacts to job market dataCPI Data & Proven Capital Preservation Methods - newser.com
Theriva Biologics reports unusual trading activity, no material changes By Investing.com - Investing.com South Africa
Theriva Biologics reports unusual trading activity, no material changes - Investing.com
Can Theriva Biologics Inc. stock rebound after recent weaknessJuly 2025 Fed Impact & Expert Approved Momentum Trade Ideas - newser.com
What institutional flow reveals about Theriva Biologics Inc.2025 Market WrapUp & Fast Momentum Stock Entry Tips - newser.com
Theriva Biologics files prospectus for up to $4 million at-the-market offering - Investing.com
Theriva Biologics Files Prospectus for Stock Offering - TradingView
Theriva Biologics (TOVX) Addresses Unusual Stock Activity - GuruFocus
What technical signals suggest for Theriva Biologics Inc. stockJuly 2025 Outlook & Daily Momentum Trading Reports - newser.com
Theriva Biologics sees no material development to account for unusual trading - TipRanks
Theriva Biologics Provides Response to Unusual Market Action - The Manila Times
Theriva (NYSE American: TOVX) says no undisclosed material updates amid unusual trading - Stock Titan
Is now a turning point for Theriva Biologics Inc.Exit Point & Safe Entry Trade Signal Reports - newser.com
Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next? - ts2.tech
Can Theriva Biologics Inc. stock expand revenue streamsQuarterly Profit Review & Community Consensus Trade Signals - newser.com
Pattern recognition hints at Theriva Biologics Inc. upside2025 Price Targets & AI Driven Stock Movement Reports - newser.com
Is Theriva Biologics Inc. (SFY0) stock a top pick for value investorsMarket Movement Recap & AI Powered Market Entry Strategies - newser.com
How analysts rate Theriva Biologics Inc. stock today2025 Price Action Summary & Risk Controlled Daily Trade Plans - newser.com
Is Theriva Biologics Inc. stock attractive for long term wealth building2025 Biggest Moves & Stock Portfolio Risk Control - newser.com
Is Theriva Biologics Inc. stock good for long term investingEarnings Beat & High Conviction Buy Zone Picks - newser.com
What earnings revisions data tells us about Theriva Biologics Inc.July 2025 Breakouts & Weekly High Potential Stock Alerts - newser.com
How to use Fibonacci retracement on Theriva Biologics Inc.Treasury Yields & AI Powered Trade Plan Recommendations - newser.com
Is Theriva Biologics Inc. stock attractive post correction2025 Trading Recap & Fast Exit and Entry Strategy Plans - newser.com
Theriva Biologics Inc. stock chart pattern explained2025 Market Sentiment & Reliable Price Action Trade Plans - newser.com
Will breakout in Theriva Biologics Inc. lead to full recovery2025 Market Outlook & Long-Term Safe Return Strategies - newser.com
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Cap:
|
Volume (24h):